التجارب السريرية بالأسفل التجارب السريرية الحالية.55 دراسات في مركز الزراعة (افتح الدراسات فقط). غربل قائمة الدراسات هذه بالموقع والحالة وغيرها. Testing the Addition of Ixazomib to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial Rochester, Minn. This phase III trial studies how well lenalidomide in combination with ixazomib works compared to lenalidomide alone in treating patients with evidence of residual multiple myeloma after stem cell transplantation. Lenalidomide may help shrink or slow the growth of multiple myeloma. Ixazomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving lenalidomide and ixazomib together may work better than giving lenalidomide alone in treating patients with evidence of residual multiple myeloma after a stem cell transplantation. A Study of Immune Cell Abnormalities Found in Individual Patients who have Type 1 Diabetes and are Waiting for Pancreas or Pancreas/Kidney Transplant Surgery Rochester, Minn. The purpose of this study is to measure and characterize specific immune cell abnormalities found in patients who have type 1 diabetes and may or may not be on the waiting list for either a pancreas alone or a pancreas and kidney transplant. A Pilot Study Examining Thiamine Deficiency in Patients Admitted to the Hospital for Liver Transplantation Jacksonville, Fla. The purpose of this study is to report the proportion of thiamine deficiency (as defined by the Mayo Clinic Laboratory reference range) in liver transplant patients. Hematopoietic Stem Cell Transplant Survivors Study (HTSS Study) Rochester, Minn. The investigators hope to find the proof of principle concept from this pilot study so that the investigators can design a clinical trial based on the results of the explanatory hypothesis. A Study to Assess Older Adults Applying Pre-transplant Comorbidity, Geriatric Assessment and Biomarkers to Predict Non-Relapse Mortality After Allogeneic Transplant (CHARM) Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this study is to determine the set of assessments and biomarkers that could together constitute a robust and valid composite health risk model for accurate personalized estimation of one year NRM. A Phase III, Prospective, Multicenter, Randomized, Controlled Clinical Trial to Demonstrate the Efficacy and Safety of Liposomal Cyclosporine A (L-CsA) Inhalation Solution Delivered via the PARI Investigational eFlow® Device plus Standard of Care versus Standard of Care Alone in the Treatment of Chronic Lung Allograft Syndrome / Bronchiolitis Obliterans Syndrome in Patients post Double Lung Transplantation (BOSTON-2) Jacksonville, Fla. The purpose of this study is to evaluate L-CsA for the treatment of bronchiolitis obliterans syndrome in adults diagnosed with Bronchiolitis Obliterans Syndrome (BOS) following double-lung transplant. Patients will receive either L-CsA (5 mg) via the PARI Investigational eFlow® Device twice daily plus Standard of Care (SoC) treatment, or SoC alone, for a period of 48 weeks. All patients will be eligible to continue in an open-label extension trial of L-CsA following completion of BOSTON-2. Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission Rochester, Minn., Jacksonville, Fla. This randomized phase III trial studies rituximab after stem cell transplant and to see how well it works compared with rituximab alone in treating patients with in minimal residual disease-negative mantle cell lymphoma in first complete remission. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Giving chemotherapy before a stem cell transplant helps kill any cancer cells that are in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. After treatment, stem cells are collected from the patient's blood and stored. More chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. Giving rituximab with or without stem cell transplant may work better in treating patients with mantle cell lymphoma. Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients (IMAGINE) Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this study is to investigate whether clazakizumab (an anti-interleukin (IL)-6 monoclonal antibody (mAb)) may be beneficial for the treatment of CABMR in recipients of a kidney transplant by inhibiting the production of Donor Specific Antibodies (DSA) and re-shaping T cell alloimmune responses. A Study to Evaluate the Effect of Inspiratory Muscle Training on Physiological Function and Clinical Outcomes Following Lung Transplant Jacksonville, Fla. The purpose of this study is to to mechanistically investigate the effect of specific inspiratory muscle training on respiratory function, exercise capacity, health-related quality-of-life, and short-term clinical outcomes in patients after lung transplant. A Study to Evaluate the Role of Mitochondrial DNA in Encoding Histocompatibility Antigens in Humans and Rejection in Heart and Lung Transplant Jacksonville, Fla. The purpose of this retrospective and prospective study is to evaluate tissue bank from donors and recipients who underwent heart and lung transplant in order to study the Role of Mitochondrial DNA in Encoding Histocompatibility Antigens in humans and rejection. التصفّح دراسات سريرية السابقالصفحة السابقة توجّه للصفحة 22 توجّه للصفحة 33 توجّه للصفحة 44 توجّه للصفحة 55 توجّه للصفحة 66 التاليالصفحة التالية طلب موعد في مايو كلينيك المواقع والسفر والإقامةبحث 25/10/2022 تبادلها عبر ارسلها على الفيس بوكارسلها في تغريدة بالأسفل التجارب السريرية الحالية.55 دراسات في مركز الزراعة (افتح الدراسات فقط). غربل قائمة الدراسات هذه بالموقع والحالة وغيرها. Testing the Addition of Ixazomib to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial Rochester, Minn. This phase III trial studies how well lenalidomide in combination with ixazomib works compared to lenalidomide alone in treating patients with evidence of residual multiple myeloma after stem cell transplantation. Lenalidomide may help shrink or slow the growth of multiple myeloma. Ixazomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving lenalidomide and ixazomib together may work better than giving lenalidomide alone in treating patients with evidence of residual multiple myeloma after a stem cell transplantation. A Pilot Study Examining Thiamine Deficiency in Patients Admitted to the Hospital for Liver Transplantation Jacksonville, Fla. The purpose of this study is to report the proportion of thiamine deficiency (as defined by the Mayo Clinic Laboratory reference range) in liver transplant patients. A Study of Immune Cell Abnormalities Found in Individual Patients who have Type 1 Diabetes and are Waiting for Pancreas or Pancreas/Kidney Transplant Surgery Rochester, Minn. The purpose of this study is to measure and characterize specific immune cell abnormalities found in patients who have type 1 diabetes and may or may not be on the waiting list for either a pancreas alone or a pancreas and kidney transplant. Hematopoietic Stem Cell Transplant Survivors Study (HTSS Study) Rochester, Minn. The investigators hope to find the proof of principle concept from this pilot study so that the investigators can design a clinical trial based on the results of the explanatory hypothesis. A Study to Assess Older Adults Applying Pre-transplant Comorbidity, Geriatric Assessment and Biomarkers to Predict Non-Relapse Mortality After Allogeneic Transplant (CHARM) Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this study is to determine the set of assessments and biomarkers that could together constitute a robust and valid composite health risk model for accurate personalized estimation of one year NRM. A Phase III, Prospective, Multicenter, Randomized, Controlled Clinical Trial to Demonstrate the Efficacy and Safety of Liposomal Cyclosporine A (L-CsA) Inhalation Solution Delivered via the PARI Investigational eFlow® Device plus Standard of Care versus Standard of Care Alone in the Treatment of Chronic Lung Allograft Syndrome / Bronchiolitis Obliterans Syndrome in Patients post Double Lung Transplantation (BOSTON-2) Jacksonville, Fla. The purpose of this study is to evaluate L-CsA for the treatment of bronchiolitis obliterans syndrome in adults diagnosed with Bronchiolitis Obliterans Syndrome (BOS) following double-lung transplant. Patients will receive either L-CsA (5 mg) via the PARI Investigational eFlow® Device twice daily plus Standard of Care (SoC) treatment, or SoC alone, for a period of 48 weeks. All patients will be eligible to continue in an open-label extension trial of L-CsA following completion of BOSTON-2. Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission Rochester, Minn., Jacksonville, Fla. This randomized phase III trial studies rituximab after stem cell transplant and to see how well it works compared with rituximab alone in treating patients with in minimal residual disease-negative mantle cell lymphoma in first complete remission. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Giving chemotherapy before a stem cell transplant helps kill any cancer cells that are in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. After treatment, stem cells are collected from the patient's blood and stored. More chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. Giving rituximab with or without stem cell transplant may work better in treating patients with mantle cell lymphoma. Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients (IMAGINE) Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this study is to investigate whether clazakizumab (an anti-interleukin (IL)-6 monoclonal antibody (mAb)) may be beneficial for the treatment of CABMR in recipients of a kidney transplant by inhibiting the production of Donor Specific Antibodies (DSA) and re-shaping T cell alloimmune responses. A Study to Evaluate the Effect of Inspiratory Muscle Training on Physiological Function and Clinical Outcomes Following Lung Transplant Jacksonville, Fla. The purpose of this study is to to mechanistically investigate the effect of specific inspiratory muscle training on respiratory function, exercise capacity, health-related quality-of-life, and short-term clinical outcomes in patients after lung transplant. A Study to Evaluate the Role of Mitochondrial DNA in Encoding Histocompatibility Antigens in Humans and Rejection in Heart and Lung Transplant Jacksonville, Fla. The purpose of this retrospective and prospective study is to evaluate tissue bank from donors and recipients who underwent heart and lung transplant in order to study the Role of Mitochondrial DNA in Encoding Histocompatibility Antigens in humans and rejection. التصفّح دراسات سريرية السابقالصفحة السابقة توجّه للصفحة 22 توجّه للصفحة 33 توجّه للصفحة 44 توجّه للصفحة 55 توجّه للصفحة 66 التاليالصفحة التالية مركز الزراعةالصفحة الرئيسية للقسمالأقسامطلب تحديد موعدمُلخّصالاختبارات والإجراءاتحالات تم علاجهاالأطباءالأطباء حسب الموقع والتخصُّصالخبرات & التصنيفاتالمواقع والسفر والإقامةالتجارب السريريةبحثتجارب Mayo Clinic وقصص المرضىالتكاليف والتأمينأخبار Mayo Clinicالنتائجإحالة المرضىالاتصال بنا الأبحاث: الأمر برمته يتوقف على المرضى الأقسامطلب تحديد موعدمُلخّصالاختبارات والإجراءاتحالات تم علاجهاالأطباءالأطباء حسب الموقع والتخصُّصالخبرات & التصنيفاتالمواقع والسفر والإقامةالتجارب السريريةبحثتجارب Mayo Clinic وقصص المرضىالتكاليف والتأمينأخبار Mayo Clinicالنتائجإحالة المرضى ORG-20199040 الأقسام والمراكز المراكز والأقسام الطبية مركز الزراعة